CEO raises AIDS medication price by 4100% overnight

Turing Pharmaceuticals CEO increases the price of its HIV/AIDS medication by 4100% overnight.

Published Tue, Sep 22 2015 4:35 AM CDT   |   Updated Tue, Nov 3 2020 12:03 PM CST

Turing Pharmaceuticals is in the headlines today for all the wrong reasons, increasing the price of their HIV/AIDS medication from $13.50 per pill to $750 per pill, overnight - an increase of an insane 4100%.

CEO raises AIDS medication price by 4100% overnight |

Daraprim, the medication in question, has been on the market for 62 years now, and is the "standard of care for food-borne illness called toxoplasmosis caused by a parasite that can severely affect those with compromised immune systems. Turing purchased the rights to the drug last month and almost immediately raised prices", reports The Washington Post.

The story gets worse, with consumers taking to Reddit to boycott the company's products, saying that they want new laws that would prevent this price gouging from happening in the future. The editor daily newsletter on the industry, John Carroll of Fierce Biotech, asked Turing's CEO, Martin Shkreli about the huge price increase. Things took to Twitter, where Carroll asked: "Let's see if we can get a statement from @MartinShkreli. Martin, your co. just hiked the price of an old drug - new to you - by 5000%. Why?". The response from Shkreli was explosive, where he straight up said: "You are such a moron".


Anthony joined the TweakTown team in 2010 and has since reviewed 100s of graphics cards. Anthony is a long time PC enthusiast with a passion of hate for games built around consoles. FPS gaming since the pre-Quake days, where you were insulted if you used a mouse to aim, he has been addicted to gaming and hardware ever since. Working in IT retail for 10 years gave him great experience with custom-built PCs. His addiction to GPU tech is unwavering.

Newsletter Subscription

Related Tags

Newsletter Subscription
Latest News
View More News
Latest Reviews
View More Reviews
Latest Articles
View More Articles